New study on hepatitis C drug treatment in vivo and in vitro
Monday, February 18, 2013 - 19:30
in Health & Medicine
Hepatitis C virus (HCV) infection affects 4 million in the US and is the prirmary cause of liver cirrhosis and liver cancer. New research shows that daclatasvir, an ant - HCV drug, has two modes of action and provides a more accurate estimate of the HCV half-life.